ARHGEF2-SSR2 Fusion FISH Probe
The ARHGEF2-SSR2 Fusion FISH Probe is used to confirm a fusion of the ARHGEF2 and SSR2 genes. The fusion of the ARHGEF2 and SSR2 genes has been associated with Breast Invasive Carcinoma, and Uterine Carcinosarcoma. These probes are FISH confirmed on normal peripheral blood in both interphase nuclei and metaphase spreads before shipment. Typical turnaround time for this product is 7-14 days after purchase.
** This product is for in vitro and research use only. This product is not intended for diagnostic use. Please note that both genes fall on the same chromosome and inter-chromosomal detection may be difficult to detect depending on the genes proximity to one another. Please consult our support staff before ordering this product to ensure that the probe can be designed to meet your specific needs.
| SKU | Test Kits | Buffer | Dye Color | Order Now |
|---|---|---|---|---|
| ARHGEF2-SSR2-20-ORGR (Standard Design) | 20 (40 μL) | 200 μL |
|
|
| ARHGEF2-SSR2-20-RERE | 20 (40 μL) | 200 μL |
|
|
| ARHGEF2-SSR2-20-REOR | 20 (40 μL) | 200 μL |
|
|
| ARHGEF2-SSR2-20-REGO | 20 (40 μL) | 200 μL |
|
|
| ARHGEF2-SSR2-20-REGR | 20 (40 μL) | 200 μL |
|
|
| ARHGEF2-SSR2-20-REAQ | 20 (40 μL) | 200 μL |
|
|
| ARHGEF2-SSR2-20-ORRE | 20 (40 μL) | 200 μL |
|
|
| ARHGEF2-SSR2-20-OROR | 20 (40 μL) | 200 μL |
|
|
| ARHGEF2-SSR2-20-ORGO | 20 (40 μL) | 200 μL |
|
|
| ARHGEF2-SSR2-20-ORAQ | 20 (40 μL) | 200 μL |
|
|
| ARHGEF2-SSR2-20-GORE | 20 (40 μL) | 200 μL |
|
|
| ARHGEF2-SSR2-20-GOOR | 20 (40 μL) | 200 μL |
|
|
| ARHGEF2-SSR2-20-GOGO | 20 (40 μL) | 200 μL |
|
|
| ARHGEF2-SSR2-20-GOGR | 20 (40 μL) | 200 μL |
|
|
| ARHGEF2-SSR2-20-GOAQ | 20 (40 μL) | 200 μL |
|
|
| ARHGEF2-SSR2-20-GRRE | 20 (40 μL) | 200 μL |
|
|
| ARHGEF2-SSR2-20-GROR | 20 (40 μL) | 200 μL |
|
|
| ARHGEF2-SSR2-20-GRGO | 20 (40 μL) | 200 μL |
|
|
| ARHGEF2-SSR2-20-GRGR | 20 (40 μL) | 200 μL |
|
|
| ARHGEF2-SSR2-20-GRAQ | 20 (40 μL) | 200 μL |
|
|
| ARHGEF2-SSR2-20-AQRE | 20 (40 μL) | 200 μL |
|
|
| ARHGEF2-SSR2-20-AQOR | 20 (40 μL) | 200 μL |
|
|
| ARHGEF2-SSR2-20-AQGO | 20 (40 μL) | 200 μL |
|
|
| ARHGEF2-SSR2-20-AQGR | 20 (40 μL) | 200 μL |
|
|
| ARHGEF2-SSR2-20-AQAQ | 20 (40 μL) | 200 μL |
|
SSR2 Gene Summary
The signal sequence receptor (SSR) is a glycosylated endoplasmic reticulum (ER) membrane receptor associated with protein translocation across the ER membrane. The SSR consists of 2 subunits, a 34-kD glycoprotein (alpha-SSR or SSR1) and a 22-kD glycoprotein (beta-SSR or SSR2). The human beta-signal sequence receptor gene (SSR2) maps to chromosome bands 1q21-q23. [provided by RefSeq, Jul 2008]
Gene Name: Signal Sequence Receptor Subunit 2
Chromosome: CHR1: 155978838 -155990758
Locus: 1q22
ARHGEF2 Gene Summary
Rho GTPases play a fundamental role in numerous cellular processes that are initiated by extracellular stimuli that work through G protein coupled receptors. The encoded protein may form complex with G proteins and stimulate rho-dependent signals. Alternatively spliced transcript variants encoding different isoforms have been identified.[provided by RefSeq, Jun 2009]
Gene Name: Rho/Rac Guanine Nucleotide Exchange Factor 2
Chromosome: CHR1: 155916629 -155948336
Locus: 1q22
Gene Diseases
The ARHGEF2 SSR2 Fusion has been associated with the following diseases:
| Disease Name |
|---|
| Breast Invasive Carcinoma |
| Uterine Carcinosarcoma |
FISH Probe Protocols
| Protocol, Procedure, or Form Name | Last Modified | Download |
|---|